Literature DB >> 12687957

[Epidemiologic and virologic study of hepatitis C virus infections in Morocco].

P Cacoub1, V Ohayon, S Sekkat, B Dumont, A Sbai, F Lunel, A Benslimane, P Godeau, M I Archane.   

Abstract

OBJECTIVES: We prospectively studied 783 consecutive Moroccan patients to define: 1) the prevalence of anti-hepatitis C virus (HCV) antibody (Ab), 2) the prevalence of other viral infections: HBs Ag, anti-HAV IgM, anti-HGV, HGV RNA, 3) the risk factors of spreading HCV infection, and 4) the distribution of HCV genotypes.
RESULTS: 60/783 (7.7%) patients had anti-HCV Ab (48 H/12 F), 26 (3.3%) HBs Ag, and 3 (0.3%) IgM anti-HAV. Anti-HGV Ab was found in 11/60 (18.3%) anti-HCV positive patients, and 6/38 (15.8%) anti-HCV negative patients. 2/22 (9%) serum anti-HCV positive and anti-HGV negative patients were positive for HGV RNA. The 60 HCV positive patients rarely had other viral infections: 3 (5%) HBs Ag, 11 (18.3%) anti-HGV positive, 2 (9%) HGV RNA positive, and none had anti-HBc, IgM anti-HAV, or anti-HIV. HCV positive patients had more often undergone transfusion of blood products (21.7 vs 5.5%; P < 0.0001), and dental treatment (55% vs 8.3%; p < 0.0001). Patients with anti-HCV Ab frequently had hepatitis lesions on liver biopsy, i.e. chronic active hepatitis (n = 44) or cirrhosis (n = 16). HCV RNA was positive in 45/60 (75%) anti-HCV positive patients. HCV genotypes were: 1b (n = 21, 47%), 2a/2c (n = 13, 29%), 1a (n = 6, 13%), et 3 (n = 1, 2%).
CONCLUSIONS: In our Moroccan population, the prevalence of HCV was high (7.7%). Other viral infections (HBV, HAV, HGV) were rare.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 12687957

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  15 in total

1.  Phylogenetic analysis of hepatitis C virus isolates from Tunisian patients.

Authors:  Ahlem Djebbi; Selma Mejri; Valerie Thiers; Henda Triki
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

Review 2.  Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: an analysis using hepatitis C virus as a proxy biomarker.

Authors:  Yousra A Mohamoud; F DeWolfe Miller; Laith J Abu-Raddad
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 3.  Hepatitis C virus infection in the Middle East and North Africa "MENA" region: injecting drug users (IDUs) is an under-investigated population.

Authors:  S Ramia; N M Melhem; K Kreidieh
Journal:  Infection       Date:  2012-01-12       Impact factor: 3.553

4.  Prevalence and factors associated with hepatitis C virus seropositivity in female individuals in islamabad, pakistan.

Authors:  Anjum Hashmi; Khalid Saleem; Jamil Ahmed Soomro
Journal:  Int J Prev Med       Date:  2010

Review 5.  Hepatitis C virus in Arab world: a state of concern.

Authors:  Mohamed A Daw; Aghnaya A Dau
Journal:  ScientificWorldJournal       Date:  2012-05-02

Review 6.  The epidemiology of hepatitis C virus in the Maghreb region: systematic review and meta-analyses.

Authors:  Fatima A Fadlalla; Yousra A Mohamoud; Ghina R Mumtaz; Laith J Abu-Raddad
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

7.  The "hidden" epidemic: a snapshot of Moroccan intravenous drug users.

Authors:  Roxana-Delia Trimbitas; Fatima Zahra Serghini; Fatiha Lazaar; Warda Baha; Abderrahim Foullous; Mohammed Essalhi; Abdelouahed El Malki; Abdelkrim Meziane Bellefquih; Abdelouaheb Bennani
Journal:  Virol J       Date:  2014-03-06       Impact factor: 4.099

8.  Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco.

Authors:  Warda Baha; Abderrahim Foullous; Noureddine Dersi; Thierry Paluku They-they; Khadija El alaoui; Nadia Nourichafi; Bouchra Oukkache; Fatiha Lazar; Soumaya Benjelloun; My Mustapha Ennaji; Abdelouhad Elmalki; Hassan Mifdal; Abdelouaheb Bennani
Journal:  BMC Public Health       Date:  2013-01-18       Impact factor: 3.295

9.  Seroprevalence of hepatitis C and associated risk factors in urban areas of Antananarivo, Madagascar.

Authors:  Charles E Ramarokoto; Fanjasoa Rakotomanana; Maherisoa Ratsitorahina; Vaomalala Raharimanga; Richter Razafindratsimandresy; Rindra Randremanana; Mala Rakoto-Andrianarivelo; Dominique Rousset; Voahangy Andrianaja; Vincent Richard; Jean-Louis Soares; Leon P Rabarijaona
Journal:  BMC Infect Dis       Date:  2008-02-29       Impact factor: 3.090

10.  MDM2 285G>C and 344T>A gene variants and their association with hepatocellular carcinoma: a Moroccan case-control study.

Authors:  Khadija Rebbani; Sayeh Ezzikouri; Agnès Marchio; Mostafa Kandil; Pascal Pineau; Soumaya Benjelloun
Journal:  Infect Agent Cancer       Date:  2014-04-07       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.